Introduction: tuberculosis (TB) remains a public health problem and is driven by HIV. Recent studies indicate that anti-retroviral therapy (ART) initiated during the first two months of anti-TB treatment (ATT) reduces risk of HIV morbidity and mortality. In Sanyati district, 14 % of TB/HIV co-infected patients were initiated on ART during TB treatment, in 2010. The study was conducted to determine the magnitude and determinants of delay in ART initiation, in TB/HIV co-infected patients. Methods: an analytic cross sectional study was conducted at three study sites in Sanyati district. The outcome was delayed ART initiation, being failure to be initiated on ART during the first two months of ATT. Respondents wer
Background: Initiation of antiretroviral therapy (ART) during tuberculosis (TB) treatment remains ch...
Background: Optimal timing for initiation of antiretroviral therapy (ART) among HIV-infected patient...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...
Introduction: tuberculosis (TB) remains a public health problem and is driven by HIV. Recent studies...
Background: Antiretroviral therapy (ART) should be given to all Human Immunodeficiency Virus (HIV)-p...
Background In India, TB and HIV co-infection remains as a serious public health problem. From 2006 o...
Objectives: To examine the prevalence and characteristics of HIV-tuberculosis (TB) co-infected patie...
Background: In the developing world, the principal cause of death among HIV-infected patients is tub...
Presented in part at the 18th International AIDS Conference, Vienna, July 18–23, 2010International a...
To compare important clinical outcomes between early and delayed initiation of antiretroviral therap...
AbstractBackgroundFor antiretroviral therapy (ART) naive human immunodeficiency virus (HIV) infected...
Co-diagnosis of HIV and tuberculosis presents a treatment dilemma. Starting both treatments at the s...
Introduction: Tuberculosis (TB) is the most common opportunistic infection (OI) and cause of death i...
[7]. Patients with a CD4+ cell count less than 200 cells/mm3, should start ART as soon as Mozambique...
Artículo de publicación ISIBackground: Antiretroviral therapy (ART) decreases mortality risk in HIV-...
Background: Initiation of antiretroviral therapy (ART) during tuberculosis (TB) treatment remains ch...
Background: Optimal timing for initiation of antiretroviral therapy (ART) among HIV-infected patient...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...
Introduction: tuberculosis (TB) remains a public health problem and is driven by HIV. Recent studies...
Background: Antiretroviral therapy (ART) should be given to all Human Immunodeficiency Virus (HIV)-p...
Background In India, TB and HIV co-infection remains as a serious public health problem. From 2006 o...
Objectives: To examine the prevalence and characteristics of HIV-tuberculosis (TB) co-infected patie...
Background: In the developing world, the principal cause of death among HIV-infected patients is tub...
Presented in part at the 18th International AIDS Conference, Vienna, July 18–23, 2010International a...
To compare important clinical outcomes between early and delayed initiation of antiretroviral therap...
AbstractBackgroundFor antiretroviral therapy (ART) naive human immunodeficiency virus (HIV) infected...
Co-diagnosis of HIV and tuberculosis presents a treatment dilemma. Starting both treatments at the s...
Introduction: Tuberculosis (TB) is the most common opportunistic infection (OI) and cause of death i...
[7]. Patients with a CD4+ cell count less than 200 cells/mm3, should start ART as soon as Mozambique...
Artículo de publicación ISIBackground: Antiretroviral therapy (ART) decreases mortality risk in HIV-...
Background: Initiation of antiretroviral therapy (ART) during tuberculosis (TB) treatment remains ch...
Background: Optimal timing for initiation of antiretroviral therapy (ART) among HIV-infected patient...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co...